Medical News Today -
4 Feb 2014 12:00
The U.S. Food and Drug Administration has approved Hetlioz (tasimelteon), a melatonin receptor agonist, to treat non-24- hour sleep-wake disorder ("non-24") in totally blind individuals. Non-24 is a chronic circadian rhythm (body clock) disorder in the blind that causes problems with the timing of sleep. This is the first FDA approval of a treatment for the disorder.Non-24 occurs in persons who are completely blind. Light does not enter their eyes and they cannot synchronize their body clock to ...
Share this Article